Paid Clinical Trials and Focus Groups by Location |
|
|
|
-
United Kingdom, England
United Kingdom
Are you healthy? Want to join a clinical trial?
We’re looking for volunteers from all walks of life but particularly people from the black community and
Conditions: Leukemia; Mucositis; Oral Complications
Interventions: Biological: epratuzumab; Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Radiation: total-body irradiation
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy; Drug: Best available antiviral drug therapy
Sponsors: Cell Medica Ltd; Wellcome Trust; Choice Pharma Ltd; Commitum AB; BioAnaLab
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Condition: Severe Aortic Valve Stenosis
Intervention: Device: Medtronic CoreValve System
Sponsor: Medtronic Bakken Research Center
Not yet recruiting - verified March 2010
Condition: Hypertension
Interventions: Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491); Drug: Azilsartan medoxomil (TAK-491)
Sponsor: Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified February 2010
Condition: Ischaemia-reperfusion (IR) Injury
Interventions: Drug: C-type natriuretic peptide (CNP); Drug: Saline; Drug: Acetylcholine
Sponsors: Queen Mary University of London; University College, London
Not yet recruiting - verified February 2010
Condition: Hormone Withdrawal Associated Symptoms
Interventions: Drug: EE20/DRSP (YAZ, BAY86-5300); Drug: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
Sponsor: Bayer
Not yet recruiting - verified February 2010
Condition: HCV Infection
Interventions: Drug: GS-9256; Drug: GS-9190; Drug: Ribavirin
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Biological: HIV-v (Low Dose); Biological: HIV-v (High Dose); Biological: HIV-v (Control)
Sponsor: PepTcell Limited
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: AZD5069
Sponsors: AstraZeneca; Quintiles
Recruiting - verified March 2010
Conditions: HIV; HIV Infections
Intervention: Drug: darunavir/ritonavir then atazanavir/ritonavir
Sponsor: St Stephens Aids Trust
Not yet recruiting - verified February 2010
Condition: Intra-abdominal Infection
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsor: Bayer
Not yet recruiting - verified March 2010
Conditions: Osteoarthritis; Pain
Interventions: Drug: MEDI-578; Drug: Placebo for MEDI-578
Sponsors: AstraZeneca; MedImmune LLC
Recruiting - verified February 2010
Conditions: Respiratory Tract Infections; Influenza
Interventions: Dietary Supplement: Cholecalciferol (Vitamin D/Vigantol oil); Dietary Supplement: Miglyol oil
Sponsors: Barts & The London NHS Trust; National Health Service, United Kingdom
Not yet recruiting - verified February 2010
Condition: Liver Cirrhosis
Intervention:
Sponsors: University College London Hospitals; Medical Research Council
Recruiting - verified April 2008
Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Condition: Psoriasis
Interventions: Drug: Ustekinumab/Methotrexate; Drug: Ustekinumab/Methotrexate
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: bendamustine; Drug: chlorambucil
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified February 2010
Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Cisplatin
Sponsor: Eli Lilly and Company
Not yet recruiting - verified February 2010
Condition: HIV Infections
Intervention: Drug: TMC278LA
Sponsor: St Stephens Aids Trust
Recruiting - verified March 2010
Conditions: Major Depressive Disorder; Healthy Volunteers
Intervention: Drug: Duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Human Immunodeficiency Virus; Hepatitis B; Hepatitis C; Human T-lymphotropic Virus I & II; Creutzfeldt-Jakob Syndrome; HIV Infections
Intervention:
Sponsors: NHS Blood and Transplant; Welsh Blood Service; Scottish National Blood Transfusion Service; Irish Blood Transfusion Service
Not yet recruiting - verified January 2010
Condition: Colorectal Neoplasms
Intervention: Device: Third Eye Retroscope
Sponsor: Avantis Medical Systems
Recruiting - verified February 2010
Condition: Hepatitis C Virus
Interventions: Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: BMS-650032; Drug: Peginterferon Alfa-2a; Drug: Peginterferon Alfa-2a; Drug: Ribavirin; Drug: Ribavirin
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Conditions: Barrett Syndrome; Barrett's Syndrome; Barrett's Esophagus; Barrett Esophagus; Adenocarcinoma
Interventions: Device: Standard endoscopic treatment of BE; Device: pCLE guided endoscopic treatment of BE
Sponsors: Mauna Kea Technologies; Cellvizio Inc.
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Castleman's Disease
Interventions: Other: Placebo; Drug: CNTO 328
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Drug: RO5083945; Drug: cetuximab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Influenza A Virus, H1N1 Subtype; Influenza B Virus; Influenza, Human; Influenza, Seasonal
Intervention: Drug: zanamivir aqueous solution
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: QTc Evaluation; Electrocardiography
Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified February 2010
Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Macular Degeneration
Interventions: Device: Epimacular Brachytherapy; Drug: Ranibizumab
Sponsors: King's College Hospital NHS Trust; NeoVista
Recruiting - verified February 2010
Conditions: Shock, Hemorrhagic; Shock, Traumatic; Acidosis, Lactic
Interventions: Drug: MP4OX; Drug: MP4OX; Drug: Ringer's Lactate solution
Sponsor: Sangart
Recruiting - verified March 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800; Drug: Placebo
Sponsor: Actelion
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Almirall, S.A.; Forest Laboratories
Recruiting - verified March 2010
Condition: Asthma
Intervention: Biological: Mepolizumab (treatment) - Severe asthma
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsor: Jerini AG
Recruiting - verified October 2009
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide once weekly; Drug: insulin detemir
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2009
Condition: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120; Drug: BIBF 1120; Drug: Sorafenib; Drug: Sorafenib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: CS-7017; Drug: Placebo
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Tachyarrhythmias; Heart Failure; Ventricular Dysfunction
Intervention: Device: Protecta Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified March 2010
Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Hemophilia B
Intervention: Genetic: Gene Transfer
Sponsors: St. Jude Children's Research Hospital; Stanford University; Katharine Dormandy Haemophilia Centre and Haemostasis Unit
Recruiting - verified March 2010
Condition: Hepatitis C
Interventions: Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo; Drug: TMC435 placebo /Peg IFNa2A/Ribavirin
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium 18mcg daily; Drug: Salmeterol 100mcg daily; Drug: Fluticasone 250mcg daily; Drug: Fluticasone 125mcg daily; Drug: Fluticasone 50mcg daily; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Neuropathic Pain
Interventions: Drug: GW856553; Drug: PLACEBO
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells
Sponsor: Kiadis Pharma
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Insulin aspart; Drug: Insulin Glulisine
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsor: Cancer Research UK
Recruiting - verified August 2009
Conditions: Stroke; Hemispatial Neglect
Interventions: Drug: Guanfacine; Drug: Placebo
Sponsors: Imperial College London; Wellcome Trust
Recruiting - verified March 2010
Condition: HPV Infections
Interventions: Biological: Cervarix; Biological: Gardasil
Sponsor: Health Protection Agency
Recruiting - verified August 2009
Condition: Sarcoidosis
Interventions: Drug: Placebo; Drug: golimumab; Drug: ustekinumab
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: Dasatinib; Drug: Lomustine
Sponsors: Bristol-Myers Squibb; European Organization for Research and Treatment of Cancer
Recruiting - verified December 2009
Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis, Arthritis,
Intervention: Drug: JNJ 38518168 or placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: SRT2104
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: paclitaxel; Drug: carboplatin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Hemophilia A
Interventions: Procedure: No Drug; Procedure: No Drug; Procedure: No Drug; Procedure: No Drug; Procedure: No Drug
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Adrenocortical Carcinoma (ACC)
Interventions: Drug: OSI-906; Other: Placebo
Sponsor: OSI Pharmaceuticals
Recruiting - verified December 2009
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Condition: Follicular Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Descending Thoracic Aortic Aneurysm
Intervention: Device: Zenith TX2(R) TAA Low-Profile Endovascular Graft
Sponsor: Cook
Recruiting - verified February 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Condition: Osteoporosis
Interventions: Drug: Actonel®; Drug: amg 162
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Advanced Non-hematologic Malignancies
Intervention: Drug: PF-04605412
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Placebo; Drug: GW856553; Drug: GW856553
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Venous Leg Ulcer
Interventions: Device: Dermagraft(R); Device: Profore
Sponsor: Advanced BioHealing, Inc.
Recruiting - verified February 2010
Conditions: Active Rheumatoid Arthritis; Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: etanercept; Drug: methotrexate
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Fracture Healing
Interventions: Drug: AMG 785 70mg; Drug: AMG 785 210mg; Drug: AMG 785 140 mg; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: bortezomib; Drug: Cyclophosphamide; Drug: bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: bortezomib; Drug: Dexamethasone
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: QTI571; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Contrast-enhanced ultrasound guided biopsy; Procedure: ultrasound guided systematic biopsy
Sponsors: Bracco Diagnostics, Inc; Bracco Imaging SpA
Recruiting - verified February 2010
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib (Sprycel)
Sponsors: European Group for Blood and Marrow Transplantation; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo, weekly; Drug: Placebo, daily
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Phenylketonuria
Interventions: Dietary Supplement: high oleic sunflower oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil
Sponsors: Ludwig-Maximilians - University of Munich; European Union
Recruiting - verified January 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: PF-03526299; Drug: Placebo; Drug: Fluticasone propionate
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: RO5024048; Drug: Pegasys; Drug: Pegasys; Drug: Copegus; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Sarcoidosis
Interventions: Procedure: EUS-FNA/EBUS-TBNA + BAL; Procedure: EBB + TBLB + BAL
Sponsor: Leiden University Medical Center
Recruiting - verified March 2009
Condition: Crohn´s Disease
Interventions: Drug: Pentasa; Drug: Placebo
Sponsor: Ferring Pharmaceuticals
Recruiting - verified February 2010
Conditions: Lymphoma, B-Cell; Lymphoma, Diffuse
Interventions: Drug: inotuzumab ozogamicin (CMC-544); Drug: rituximab
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Alogliptin and metformin; Drug: Alogliptin and metformin; Drug: Glipizide and metformin
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Conditions: Arthroplasty, Replacement; Thromboembolism
Intervention:
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol 150 µg; Drug: Tiotropium
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Conditions: Arthroplasty, Replacement; Thromboembolism
Intervention:
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Condition: In Vitro Fertilization
Interventions: Drug: Progesterone; Drug: Progesterone
Sponsor: IBSA Institut Biochimique SA
Recruiting - verified February 2010
Condition: HIV-1
Interventions: Drug: UK-453, 061; Drug: UK-453, 061; Drug: EFV +TVA
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: HIV-1
Interventions: Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: RO5072759; Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone); Drug: FC(fludarabine,cyclophosphamide)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Aortic Valve Stenosis
Intervention: Device: Sapien XT™ transcatheter heart valve and its transfemoral delivery system
Sponsor: Edwards Lifesciences
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Pulmonary Hypertension
Interventions: Drug: Riociguat (BAY63-2521); Drug: Riociguat (BAY63-2521); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Neoplasms
Interventions: Drug: BIBW2992; Drug: BIBW 2992; Drug: BIBW 2992; Drug: BIBW 2992; Drug: Paclitaxel; Drug: Paclitaxel; Drug: Paclitaxel; Drug: Bevacizumab; Drug: Carboplatin; Drug: Carboplatin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Urinary Bladder, Overactive
Interventions: Drug: Placebo; Drug: Fesoterodine fumarate
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Acute Lung Injury; Acute Respiratory Distress Syndrome
Intervention: Drug: Interferon Beta
Sponsor: Faron Pharmaceuticals Ltd
Recruiting - verified March 2009
Conditions: Soft Tissue Sarcomas; Translocation-Related Sarcomas (TRS)
Intervention: Drug: Trabectedin, ET 743 and Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified February 2010
Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102; Drug: Panitumumab + AMG 479; Drug: AMG 479; Drug: AMG 102; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
Condition: Anaplastic Astrocytoma
Interventions: Drug: trabedersen; Drug: temozolomide or carmustine for infusion; Device: Drug delivery system for administration of AP 12009; Procedure: Placement of Drug Delivery System
Sponsor: Antisense Pharma
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Acromegaly
Intervention:
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Neuroendocrine Tumors
Intervention:
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Non Small Cell Lung Cancer
Interventions: Biological: IMC-1121B; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Gaucher Disease
Intervention: Drug: Taliglucerase alfa
Sponsor: Protalix
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified February 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Conditions: Diabetic Retinopathy; Diabetes Complications
Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: atomoxetine hydrochloride; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Candida; Candidiasis
Interventions: Drug: Anidulafungin; Drug: Fluconazole; Drug: Voriconazole
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: ambrisentan
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Thromboembolism
Interventions: Drug: Dabigatran etexilate; Drug: Warfarin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Opioid-induced Constipation
Interventions: Drug: Methylnaltrexone bromide (MOA-728); Drug: Placebo
Sponsors: Wyeth; Progenics Pharmaceuticals, Inc.
Recruiting - verified February 2010
Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Conditions: Meningococcal Infections; Pneumococcal Infections
Interventions: Biological: NeisVacC (Meningococcal C conjugate vaccine); Biological: Menjugate (Meningococcal C conjugate vaccine)
Sponsors: Health Protection Agency; Institute of Child Health; National Institute of Biological Standards and Control
Recruiting - verified January 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified February 2010
Conditions: Transfusional Iron Overload; Transfusional Hemosiderosis
Interventions: Drug: Deferasirox; Drug: Deferoxamine
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Moderate Risk of CVD
Interventions: Drug: Aspirin (Acetylsalicylic acid, BAYE4465); Drug: Placebo
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Periodic Paralysis
Interventions: Drug: Dichlorphenamide; Drug: Placebo
Sponsors: University of Rochester; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2010
Condition: Lymphoma, B-Cell
Interventions: Drug: bevacizumab [Avastin]; Drug: R-CHOP; Drug: Placebo
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Xeloda
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Cancer
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsor: St. Bartholomew's Hospital
Recruiting - verified September 2007
Conditions: Venous Thrombosis; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Enoxaparin
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Neoplasms
Intervention: Drug: SU011248
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: steroids (prednisone or prednisolone) + MMF; Drug: abatacept; Drug: abatacept
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Mitral Regurgitation; Coronary Artery Disease
Interventions: Procedure: Mitral annuloplasty; Procedure: Coronary Artery Bypass Graft Surgery
Sponsors: Imperial College London; Department of Health, United Kingdom; British Heart Foundation; British Medical Association; Hammersmith Hospitals NHS Trust; St Mary's NHS Trust; King's College Hospital NHS Trust; Glasgow Royal Infirmary; Golden Jubilee National Hospital; University Hospitals, Leicester; Nottingham University Hospitals NHS Trust; Medical University of Silesia; Papworth Hospital; Central Manchester University Hospitals NHS Foundation Trust; United Bristol Healthcare NHS Trust; Blackpool, Flyde and Wyre Hospitals NHS Foundation Trust; Oxford Radcliffe Hospitals NHS Trust
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Premature Labor
Interventions: Drug: Placebo; Drug: GSK221149A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified March 2008
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Thromboembolism
Interventions: Drug: Dabigatran; Drug: Warfarin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Procedure: orchiectomy
Sponsor: Medical Research Council
Recruiting - verified March 2008
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsor: Boehringer Ingelheim Pharmaceuticals
Available - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
All Locations ... United Kingdom » ... England » ... London 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
